A case series exploring the efficacy, secondary failure, paradoxical event & relapse with ustekinumab therapy in chronic plaque psoriasis

Ustekinumab is an anti-IL12/23 biologic agent used for treatment of psoriasis with excellent efficacy. However, there are therapeutic obstacles such as secondary failure and paradoxical event. Disease relapse upon discontinuation of therapy is common. A case series was performed on patients wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Rasimah Ismail,, Adawiyah Jamil,, Norazirah Md Nor,
Format: Article
Language:English
Published: Pusat Perubatan Universiti Kebangsaan Malaysia 2020
Online Access:http://journalarticle.ukm.my/16277/1/15_ms0426_pdf_43746.pdf
http://journalarticle.ukm.my/16277/
https://www.medicineandhealthukm.com/toc/15/2
Tags: Add Tag
No Tags, Be the first to tag this record!
id my-ukm.journal.16277
record_format eprints
spelling my-ukm.journal.162772021-03-16T02:45:20Z http://journalarticle.ukm.my/16277/ A case series exploring the efficacy, secondary failure, paradoxical event & relapse with ustekinumab therapy in chronic plaque psoriasis Rasimah Ismail, Adawiyah Jamil, Norazirah Md Nor, Ustekinumab is an anti-IL12/23 biologic agent used for treatment of psoriasis with excellent efficacy. However, there are therapeutic obstacles such as secondary failure and paradoxical event. Disease relapse upon discontinuation of therapy is common. A case series was performed on patients with chronic plaque psoriasis who received ustekinumab between 2013 to 2018 at a tertiary referral centre. Demographics, clinical characteristics, duration of therapy, efficacy, treatment complications, rate and pattern of relapses were determined from the patients’ medical records. Out of 8 patients, 6 (75%) patients were males. There were 6 (75%) biologic-naïve patients. Median age was 41.5 years (IQR26.8-48.3), median duration of psoriasis was 16.5 years (IQR6.5-23.0). Median duration to achieve Psoriasis Activity and Severity Index (PASI)75 was 16 weeks and median total duration of treatment was 102 weeks. All patients achieved treatment success. PASI75 at week 12 was achieved by 37.5%, a median of 16 weeks was required to achieve at least PASI 75 but 6 (75%) attained PASI 90 by then. One patient (12.5%) developed paradoxical event with pustular and plaques. Secondary failure occurred in 2 (25%) patients. All patients relapsed after treatment discontinuation, relapse occurred at median of 40 weeks. Most (71%) developed plaques on relapse but 25% developed plaques and pustules. All but one patient required further biological agent for treatment of relapse. Ustekinumab was efficacious in all patients. Treatment success was achieved slightly later than standard duration. The rare occurrences of secondary failure and paradoxical were observed. Relapse was inevitable, new onset pustular eruptions featured in relapses. Pusat Perubatan Universiti Kebangsaan Malaysia 2020-12 Article PeerReviewed application/pdf en http://journalarticle.ukm.my/16277/1/15_ms0426_pdf_43746.pdf Rasimah Ismail, and Adawiyah Jamil, and Norazirah Md Nor, (2020) A case series exploring the efficacy, secondary failure, paradoxical event & relapse with ustekinumab therapy in chronic plaque psoriasis. Medicine & Health, 15 (2). pp. 153-163. ISSN 2289-5728 https://www.medicineandhealthukm.com/toc/15/2
institution Universiti Kebangsaan Malaysia
building Tun Sri Lanang Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Kebangsaan Malaysia
content_source UKM Journal Article Repository
url_provider http://journalarticle.ukm.my/
language English
description Ustekinumab is an anti-IL12/23 biologic agent used for treatment of psoriasis with excellent efficacy. However, there are therapeutic obstacles such as secondary failure and paradoxical event. Disease relapse upon discontinuation of therapy is common. A case series was performed on patients with chronic plaque psoriasis who received ustekinumab between 2013 to 2018 at a tertiary referral centre. Demographics, clinical characteristics, duration of therapy, efficacy, treatment complications, rate and pattern of relapses were determined from the patients’ medical records. Out of 8 patients, 6 (75%) patients were males. There were 6 (75%) biologic-naïve patients. Median age was 41.5 years (IQR26.8-48.3), median duration of psoriasis was 16.5 years (IQR6.5-23.0). Median duration to achieve Psoriasis Activity and Severity Index (PASI)75 was 16 weeks and median total duration of treatment was 102 weeks. All patients achieved treatment success. PASI75 at week 12 was achieved by 37.5%, a median of 16 weeks was required to achieve at least PASI 75 but 6 (75%) attained PASI 90 by then. One patient (12.5%) developed paradoxical event with pustular and plaques. Secondary failure occurred in 2 (25%) patients. All patients relapsed after treatment discontinuation, relapse occurred at median of 40 weeks. Most (71%) developed plaques on relapse but 25% developed plaques and pustules. All but one patient required further biological agent for treatment of relapse. Ustekinumab was efficacious in all patients. Treatment success was achieved slightly later than standard duration. The rare occurrences of secondary failure and paradoxical were observed. Relapse was inevitable, new onset pustular eruptions featured in relapses.
format Article
author Rasimah Ismail,
Adawiyah Jamil,
Norazirah Md Nor,
spellingShingle Rasimah Ismail,
Adawiyah Jamil,
Norazirah Md Nor,
A case series exploring the efficacy, secondary failure, paradoxical event & relapse with ustekinumab therapy in chronic plaque psoriasis
author_facet Rasimah Ismail,
Adawiyah Jamil,
Norazirah Md Nor,
author_sort Rasimah Ismail,
title A case series exploring the efficacy, secondary failure, paradoxical event & relapse with ustekinumab therapy in chronic plaque psoriasis
title_short A case series exploring the efficacy, secondary failure, paradoxical event & relapse with ustekinumab therapy in chronic plaque psoriasis
title_full A case series exploring the efficacy, secondary failure, paradoxical event & relapse with ustekinumab therapy in chronic plaque psoriasis
title_fullStr A case series exploring the efficacy, secondary failure, paradoxical event & relapse with ustekinumab therapy in chronic plaque psoriasis
title_full_unstemmed A case series exploring the efficacy, secondary failure, paradoxical event & relapse with ustekinumab therapy in chronic plaque psoriasis
title_sort case series exploring the efficacy, secondary failure, paradoxical event & relapse with ustekinumab therapy in chronic plaque psoriasis
publisher Pusat Perubatan Universiti Kebangsaan Malaysia
publishDate 2020
url http://journalarticle.ukm.my/16277/1/15_ms0426_pdf_43746.pdf
http://journalarticle.ukm.my/16277/
https://www.medicineandhealthukm.com/toc/15/2
_version_ 1695531689564962816
score 13.214268